What is the recommended duration of ticagrelor (Brilinta) therapy after cardiac stent implantation?

Duration of Brilinta (Ticagrelor) After Cardiac Stent

For patients receiving a stent during PCI for acute coronary syndrome (ACS), ticagrelor 90 mg twice daily should be given for at least 12 months in combination with aspirin. 1, 2, 3, 1

Standard Recommendations by Clinical Scenario

Acute Coronary Syndrome (ACS) with Stent Placement

• Duration: Minimum 12 months of dual antiplatelet therapy (DAPT)
• Dosing: Ticagrelor 90 mg twice daily + aspirin 81 mg daily 1, 2, 3
• Applies to: Both bare-metal stents (BMS) and drug-eluting stents (DES) 1
• Loading dose: 180 mg ticagrelor at time of PCI 1, 2

Non-ACS (Stable Coronary Disease) with DES

• Duration: At least 12 months if not at high bleeding risk
• Agent: Guidelines primarily recommend clopidogrel 75 mg daily for this indication 1, 2
• Note: Ticagrelor is specifically recommended for ACS patients; evidence for routine use in stable disease is weaker 4

Non-ACS with BMS

• Duration: Minimum 1 month, ideally up to 12 months
• **Shortened to 2 weeks minimum if high bleeding risk 1

Important Modifications and Considerations

Early Discontinuation

If bleeding risk outweighs benefit, earlier discontinuation (<12 months) is reasonable 2. This is a Class IIa recommendation, meaning it's reasonable to consider but requires careful risk-benefit assessment.

Extension Beyond 12 Months

Continuation beyond 12 months may be considered in patients with DES, but this is a Class IIb recommendation (weaker evidence) 2

Aspirin Dosing with Ticagrelor

Critical: Aspirin dose must be 81 mg daily when used with ticagrelor 3. Higher aspirin doses (up to 325 mg) are acceptable with clopidogrel but not with ticagrelor.

Emerging Evidence on Shortened DAPT

Recent high-quality trials have challenged the standard 12-month duration:

The T-PASS trial (2024) 5 showed that stopping aspirin within 1 month (median 16 days) for ticagrelor monotherapy was superior to 12-month DAPT in ACS patients, with:

• Lower net clinical events (2.8% vs 5.2%, HR 0.54)
• Significantly reduced major bleeding (1.2% vs 3.4%, HR 0.35)
• No increase in ischemic events

The TICO trial (2020) 6 demonstrated that ticagrelor monotherapy after 3 months of DAPT reduced net adverse events compared to 12-month DAPT (3.9% vs 5.9%, HR 0.66), driven primarily by bleeding reduction.

The TWILIGHT trial (2019) 7 showed ticagrelor monotherapy after 3 months reduced bleeding without increasing ischemic events in high-risk PCI patients.

However, these shortened strategies are not yet incorporated into major guidelines 1, 2, 3, 8. The 2024 ESC guidelines 4 acknowledge this data but maintain standard recommendations, noting the evidence is "weaker than for other recommended antithrombotic strategies."

Practical Algorithm

For ACS patients with stent:

1. Start ticagrelor 90 mg twice daily + aspirin 81 mg daily
2. Continue for 12 months (guideline standard)
3. Consider early discontinuation only if:
   • High bleeding risk (prior GI bleed, need for anticoagulation, advanced age with multiple risk factors)
   • Bleeding event occurs on therapy
   • Patient cannot tolerate medication

For stable CAD with DES:

1. Clopidogrel 75 mg daily + aspirin is preferred 1, 4
2. If ticagrelor used, continue 12 months minimum
3. Aspirin must be 81 mg (not higher doses)

After 12 months:

1. Continue aspirin indefinitely 1, 2
2. Stop P2Y12 inhibitor (standard approach)
3. Extension beyond 12 months is optional (Class IIb) 2

Common Pitfalls

• Do not use aspirin >100 mg daily with ticagrelor - this increases bleeding without added benefit 3, 9
• Do not routinely use ticagrelor for stable CAD - guidelines support this primarily for ACS 4, 8
• Do not stop DAPT in first month without compelling reason - stent thrombosis risk is highest early 1, 2
• Do not confuse prasugrel and ticagrelor recommendations - they have different evidence bases and contraindications 8

The guideline-recommended duration remains 12 months for ACS patients, though emerging evidence suggests shorter durations with ticagrelor monotherapy may be beneficial in selected patients. Until guidelines are updated, the 12-month standard should be followed unless specific high bleeding risk factors necessitate earlier discontinuation.